Open access · CC-BY
via OpenAlex
Biomarkers in COVID-19: An Up-To-Date Review
Madhusudan Samprathi, Muralidharan Jayashree
Frontiers in Pediatrics · 2021 · ▲ 301 citations
Abstract
The ongoing pandemic of coronavirus disease 2019 (COVID-19) poses several challenges to clinicians. Timely diagnosis and hospitalization, risk stratification, effective utilization of intensive care services, selection of appropriate therapies, monitoring and timely discharge are essential to save the maximum number of lives. Clinical assessment is indispensable, but laboratory markers, or biomarkers, can provide additional, objective information which can significantly impact these components of patient care. COVID-19 is not a localized respiratory infection but a multisystem disease caused by a diffuse systemic process involving a complex interplay of the immunological, inflammatory and coagulative cascades. The understanding of what the virus does to the body and how the body reacts to it has uncovered a gamut of potential biomarkers. This review discusses the different classes of biomarkers - immunological, inflammatory, coagulation, hematological, cardiac, biochemical and miscellaneous - in terms of their pathophysiological basis followed by the current evidence. Differences between children and adults are highlighted. The role of biomarkers in the diagnosis and management of Multisystem Inflammatory Syndrome in Children (MIS-C) is reviewed. The correlation of biomarkers with clinical and radiological features and the viral load, temporal evolution and the effect of treatment remain to be studied in detail. Which biomarker needs to be evaluated when and in whom, and how best this information can contribute to patient care are questions which currently lack convincing answers. With the evidence currently available broad guidelines on the rational use of available biomarkers are presented. Integrating clinical and laboratory data, monitoring trends rather than a single value, correlating with the natural course of the disease and tailoring guidelines to the individual patient and healthcare setting are essential.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fped.2020.607647
- Canonical
- link ↗
- Fetched
- 2026-07-28 MST
Cite this
APA
Samprathi, M., & Jayashree, M. (2021). Biomarkers in COVID-19: An Up-To-Date Review. <em>Frontiers in Pediatrics</em>. https://doi.org/10.3389/fped.2020.607647
Vancouver
Samprathi M, Jayashree M. Biomarkers in COVID-19: An Up-To-Date Review. Frontiers in Pediatrics. 2021. doi:10.3389/fped.2020.607647.
BibTeX
@article{madhusudan2021Biomar,
title = {Biomarkers in COVID-19: An Up-To-Date Review},
author = {Madhusudan Samprathi and Muralidharan Jayashree},
journal = {Frontiers in Pediatrics},
year = {2021},
doi = {10.3389/fped.2020.607647},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Clinical Chemistry and Laboratory Medicine (CCLM) 2020
Open access · OA
Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis
Immunological Reviews 2022
Open access · CC-BY
Transcriptomics for child and adolescent tuberculosis*
Asian Journal of Medical Sciences 2021
Open access · CC-BY
Association of inflammatory biomarkers with radiological severity for COVID-19 patient risk stratification: An Indian perspective
2026
Open access · CC-BY
PO:02:052 Performance of inflammatory biomarker models in determining high disease activity in systemic lupus erythematosus
International Journal of Science and Research Archive 2024
Open access · CC-BY
Significance of inflammatory biomarkers in clinical diagnostics: Erythrocyte sedimentation rate versus other inflammatory biomarkers: A review
American Journal of Hematology 2020
Open access · OA